Letter to the Editor: Lapatinib Confounds Post-Hoc Weight Loss Analysis in the ALTTO Trial

Authors: Neil M. Iyengar MD1 and Jennifer A. Ligibel MD2
View More View Less
  • 1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
  • | 2 Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 1.

    Martel S, Lambertini M, Agbor-Tarh D, et al. Body mass index and weight change in patients with HER2-positive early breast cancer: exploratory analysis of the ALTTO BIG 2-06 trial. J Natl Compr Canc Netw 2021;19:181189.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Lohmann AE, Soldera SV, Pimentel I, et al. Association of obesity with breast cancer outcome in relation to cancer subtypes: a meta-analysis. J Natl Cancer Inst 2021;djab023.

    • Search Google Scholar
    • Export Citation
  • 3.

    Yerushalmi R, Dong B, Chapman JW, et al. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 2017;28:15601568.

  • 4.

    Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016;34:10341042.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone, trastuzumab alone, their sequence, or their combination in the adjuvant treatment of HER2-positive early breast cancer [abstract]. J Clin Oncol 2014;32(Suppl):Abstract LBA4.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 24 24 24
PDF Downloads 17 17 17
EPUB Downloads 0 0 0